A novel balanced chromosomal translocation found in subjects with schizophrenia and schizotypal personality disorder: Altered l-serine level associated with disruption of PSAT1 gene expression

Neuroscience Research

Volumn 69, Issue 2, 2011, Pages 154-160

  Ozeki, Yuji ^a,f   Pickard, Benjamin S ^b,h   Kano, Shin Ichi ^c   Malloy, Mary P ^b   Zeledon, Mariela ^c   Sun, Daniel Q ^c   Fujii, Kumiko ^a   Wakui, Keiko ^d   Shirayama, Yukihiko ^e   Fukushima, Yoshimitsu ^d   Kunugi, Hiroshi ^f   Hashimoto, Kenji ^g   Muir, Walter J ^b   Blackwood, Douglas H ^b   Sawa, Akira ^c  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e TEIKYO UNIVERSITY CHIBA MEDICAL CENTER   (Japan)

^f NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

^g CHIBA UNIVERSITY   (Japan)

^h UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

Balanced chromosomal translocation; D Serine; Expression; Glutamate; Glycine; L Serine; PSAT1; Schizophrenia

Indexed keywords

GLUTAMIC ACID; SERINE;

AMINO ACID BLOOD LEVEL; ANAMNESIS; ARTICLE; CHROMOSOME 3Q; CHROMOSOME 9Q; CHROMOSOME TRANSLOCATION; CLINICAL FEATURE; GENE; GENE EXPRESSION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PSAT1 GENE; RAT; SCHIZOPHRENIA; SCHIZOTYPAL PERSONALITY DISORDER;

AGE OF ONSET; ANIMALS; ASTROCYTES; BLOTTING, WESTERN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMOSOMES, HUMAN, PAIR 9; FEMALE; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; GLUTAMIC ACID; HUMANS; MALE; MIDDLE AGED; PEDIGREE; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SCHIZOPHRENIA; SERINE; TRANSAMINASES; TRANSLOCATION, GENETIC; YOUNG ADULT;

EID: 78650307890     PISSN: 01680102     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neures.2010.10.003     Document Type: Article

References (51)

1. Antflick J.E., Vetiska S., Baizer J.S., Yao Y., Baker G.B., Hampson D.R. l-Serine-O-phosphate in the central nervous system. Brain Res. 2009, 1300:1-13.
2. Baum A.E., Akula N., Cabanero M., Cardona I., Corona W., Klemens B., Schulze T.G., Cichon S., Rietschel M., Nothen M.M., Georgi A., Schumacher J., Schwarz M., Abou Jamra R., Hofels S., Propping P., Satagopan J., Detera-Wadleigh S.D., Hardy J., McMahon F.J. A genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorder. Mol. Psychiatry 2008, 13:197-207.
3. Bendikov I., Nadri C., Amar S., Panizzutti R., De Miranda J., Wolosker H., Agam G. A CSF and postmortem brain study of d-serine metabolic parameters in schizophrenia. Schizophr. Res. 2007, 90:41-51.
4. Buchanan R.W., Freedman R., Javitt D.C., Abi-Dargham A., Lieberman J.A. Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. Schizophr. Bull. 2007, 33:1120-1130.
5. Cascella N.G., Macciardi F., Cavallini C., Smeraldi E. d-Cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label study. J. Neural Transm. Gen. Sect. 1994, 95:105-111.
6. Chumakov I., Blumenfeld M., Guerassimenko O., Cavarec L., Palicio M., Abderrahim H., Bougueleret L., Barry C., Tanaka H., La Rosa P., Puech A., Tahri N., Cohen-Akenine A., Delabrosse S., Lissarrague S., Picard F.P., Maurice K., Essioux L., Millasseau P., Grel P., Debailleul V., Simon A.M., Caterina D., Dufaure I., Malekzadeh K., Belova M., Luan J.J., Bouillot M., Sambucy J.L., Primas G., Saumier M., Boubkiri N., Martin-Saumier S., Nasroune M., Peixoto H., Delaye A., Pinchot V., Bastucci M., Guillou S., Chevillon M., Sainz-Fuertes R., Meguenni S., Aurich-Costa J., Cherif D., Gimalac A., Van Duijn C., Gauvreau D., Ouellette G., Fortier I., Raelson J., Sherbatich T., Riazanskaia N., Rogaev E., Raeymaekers P., Aerssens J., Konings F., Luyten W., Macciardi F., Sham P.C., Straub R.E., Weinberger D.R., Cohen N., Cohen D. Genetic and physiological data implicating the new human gene G72 and the gene for d-amino acid oxidase in schizophrenia. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:13675-13680.
7. de Koning T.J., Duran M., Dorland L., Gooskens R., Van Schaftingen E., Jaeken J., Blau N., Berger R., Poll-The B.T. Beneficial effects of l-serine and glycine in the management of seizures in 3-phosphoglycerate dehydrogenase deficiency. Ann. Neurol. 1998, 44:261-265.
8. de Koning T.J., Klomp L.W. Serine-deficiency syndromes. Curr. Opin. Neurol. 2004, 17:197-204.
9. Elia J., Gai X., Xie H.M., Perin J.C., Geiger E., Glessner J.T., D'Arcy M., Deberardinis R., Frackelton E., Kim C., Lantieri F., Muganga B.M., Wang L., Takeda T., Rappaport E.F., Grant S.F., Berrettini W., Devoto M., Shaikh T.H., Hakonarson H., White P.S. Rare structural variants found in attention-deficit hyperactivity disorder are preferentially associated with neurodevelopmental genes. Mol. Psychiatry 2009, 15. 1122.
10. Ferreira M.A., O'Donovan M.C., Meng Y.A., Jones I.R., Ruderfer D.M., Jones L., Fan J., Kirov G., Perlis R.H., Green E.K., Smoller J.W., Grozeva D., Stone J., Nikolov I., Chambert K., Hamshere M.L., Nimgaonkar V.L., Moskvina V., Thase M.E., Caesar S., Sachs G.S., Franklin J., Gordon-Smith K., Ardlie K.G., Gabriel S.B., Fraser C., Blumenstiel B., Defelice M., Breen G., Gill M., Morris D.W., Elkin A., Muir W.J., McGhee K.A., Williamson R., MacIntyre D.J., MacLean A.W., St C.D., Robinson M., Van Beck M., Pereira A.C., Kandaswamy R., McQuillin A., Collier D.A., Bass N.J., Young A.H., Lawrence J., Ferrier I.N., Anjorin A., Farmer A., Curtis D., Scolnick E.M., McGuffin P., Daly M.J., Corvin A.P., Holmans P.A., Blackwood D.H., Gurling H.M., Owen M.J., Purcell S.M., Sklar P., Craddock N. Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder. Nat. Genet. 2008, 40:1056-1058.
11. Fujii K., Maeda K., Hikida T., Mustafa A.K., Balkissoon R., Xia J., Yamada T., Ozeki Y., Kawahara R., Okawa M., Huganir R.L., Ujike H., Snyder S.H., Sawa A. Serine racemase binds to PICK1: potential relevance to schizophrenia. Mol. Psychiatry 2006, 11:150-157.
12. Fukushima T., Kawai J., Imai K., Toyo'oka T. Simultaneous determination of d- and l-serine in rat brain microdialysis sample using a column-switching HPLC with fluorimetric detection. Biomed. Chromatogr. 2004, 18:813-819.
13. Gill M., Donohoe G., Corvin A. What have the genomics ever done for the psychoses?. Psychol. Med. 2010, 40:529-540.
14. Hart C.E., Race V., Achouri Y., Wiame E., Sharrard M., Olpin S.E., Watkinson J., Bonham J.R., Jaeken J., Matthijs G., Van Schaftingen E. Phosphoserine aminotransferase deficiency: a novel disorder of the serine biosynthesis pathway. Am. J. Hum. Genet. 2007, 80:931-937.
15. Hashimoto K., Engberg G., Shimizu E., Nordin C., Lindström L., Iyo M. Elevated glutamine/glutamate ratio in cerebrospinal fluid of first episode and drug naive schizophrenic patients. BMC Psychiatry 2005, 5:6.
16. Hashimoto K., Fukushima T., Shimizu E., Komatsu N., Watanabe H., Shinoda N., Nakazato M., Kumakiri C., Okada S., Hasegawa H., Imai K., Iyo M. Decreased serum levels of d-serine in patients with schizophrenia: evidence in support of the N-methyl-d-aspartate receptor hypofunction hypothesis of schizophrenia. Arch. Gen. Psychiatry 2003, 60:572-576.
17. Heresco-Levy U., Ermilov M., Lichtenberg P., Bar G., Javitt D.C. High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Biol. Psychiatry 2004, 55:165-171.
18. Heresco-Levy U., Javitt D.C. Comparative effects of glycine and d-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis. Schizophr. Res. 2004, 66:89-96.
19. Heresco-Levy U., Javitt D.C., Ebstein R., Vass A., Lichtenberg P., Bar G., Catinari S., Ermilov M. d-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol. Psychiatry 2005, 57:577-585.
20. Hovatta I., Varilo T., Suvisaari J., Terwilliger J.D., Ollikainen V., Arajarvi R., Juvonen H., Kokko-Sahin M.L., Vaisanen L., Mannila H., Lonnqvist J., Peltonen L. A genomewide screen for schizophrenia genes in an isolated Finnish subpopulation, suggesting multiple susceptibility loci. Am. J. Hum. Genet. 1999, 65:1114-1124.
21. Huang J., Perlis R.H., Lee P.H., Rush A.J., Fava M., Sachs G.S., Lieberman J., Hamilton S.P., Sullivan P., Sklar P., Purcell S., Smoller J.W. Cross-disorder genomewide analysis of schizophrenia, bipolar disorder, and depression. Am. J. Psychiatry. 2010, 167:1254-1263.
22. Jaeken J., Detheux M., Fryns J.P., Collet J.F., Alliet P., Van Schaftingen E. Phosphoserine phosphatase deficiency in a patient with Williams syndrome. J. Med. Genet. 1997, 34:594-596.
23. Jaeken J., Detheux M., Van Maldergem L., Foulon M., Carchon H., Van Schaftingen E. 3-Phosphoglycerate dehydrogenase deficiency: an inborn error of serine biosynthesis. Arch. Dis. Childhood 1996, 74:542-545.
24. Javitt D.C. Glutamate as a therapeutic target in psychiatric disorders. Mol. Psychiatry 2004, 9:984-997.
25. Javitt D.C. Glycine transport inhibitors and the treatment of schizophrenia. Biol. Psychiatry 2008, 63:6-8.
26. Kamnasaran D., Muir W.J., Ferguson-Smith M.A., Cox D.W. Disruption of the neuronal PAS3 gene in a family affected with schizophrenia. J. Med. Genet. 2003, 40:325-332.
27. Kantrowitz J.T., Malhotra A.K., Cornblatt B., Silipo G., Balla A., Suckow R.F., D'Souza C., Saksa J., Woods S.W., Javitt D.C. High dose d-serine in the treatment of schizophrenia. Schizophr. Res. 2010, 121:125-130.
28. Kleinjan D.J., Coutinho P. Cis-ruption mechanisms: disruption of cis-regulatory control as a cause of human genetic disease. Brief Funct. Genomic Proteomic 2009, 8:317-332.
29. Labrie V., Roder J.C. The involvement of the NMDA receptor d-serine/glycine site in the pathophysiology and treatment of schizophrenia. Neurosci. Biobehav. Rev. 2010, 34:351-372.
30. Lane H.Y., Chang Y.C., Liu Y.C., Chiu C.C., Tsai G.E. Sarcosine or d-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Arch. Gen. Psychiatry 2005, 62:1196-1204.
31. Lane H.Y., Huang C.L., Wu P.L., Liu Y.C., Chang Y.C., Lin P.Y., Chen P.W., Tsai G. Glycine transporter I inhibitor N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. Biol. Psychiatry 2006, 60:645-649.
32. McInnis M.G., Dick D.M., Willour V.L., Avramopoulos D., MacKinnon D.F., Simpson S.G., Potash J.B., Edenberg H.J., Bowman E.S., McMahon F.J., Smiley C., Chellis J.L., Huo Y., Diggs T., Meyer E.T., Miller M., Matteini A.T., Rau N.L., DePaulo J.R., Gershon E.S., Badner J.A., Rice J.P., Goate A.M., Detera-Wadleigh S.D., Nurnberger J.I., Reich T., Zandi P.P., Foroud T.M. Genome-wide scan and conditional analysis in bipolar disorder: evidence for genomic interaction in the National Institute of Mental Health genetics initiative bipolar pedigrees. Biol. Psychiatry 2003, 54:1265-1273.
33. Morita Y., Ujike H., Tanaka Y., Otani K., Kishimoto M., Morio A., Kotaka T., Okahisa Y., Matsushita M., Morikawa A., Hamase K., Zaitsu K., Kuroda S. A genetic variant of the serine racemase gene is associated with schizophrenia. Biol. Psychiatry 2007, 61:1200-1203.
34. Muir W.J., Pickard B.S., Blackwood D.H. Chromosomal abnormalities and psychosis. Br. J. Psychiatry 2006, 188:501-503.
35. Nakano I., Dougherty J.D., Kim K., Klement I., Geschwind D.H., Kornblum H.I. Phosphoserine phosphatase is expressed in the neural stem cell niche and regulates neural stem and progenitor cell proliferation. Stem Cells 2007, 25:1975-1984.
36. Okamoto N., Hori S., Akazawa C., Hayashi Y., Shigemoto R., Mizuno N., Nakanishi S. Molecular characterization of a new metabotropic glutamate receptor mGluR7 coupled to inhibitory cyclic AMP signal transduction. J. Biol. Chem. 1994, 269:1231-1236.
37. Otsubo T., Tanaka K., Koda R., Shinoda J., Sano N., Tanaka S., Aoyama H., Mimura M., Kamijima K. Reliability and validity of Japanese version of the Mini-International Neuropsychiatric Interview. Psychiatry Clin. Neurosci. 2005, 59:517-526.
38. Pickard B.S., Malloy M.P., Porteous D.J., Blackwood D.H., Muir W.J. Disruption of a brain transcription factor NPAS3, is associated with schizophrenia and learning disability. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 2005, 136B:26-32.
39. Pineda M., Vilaseca M.A., Artuch R., Santos S., Garcia Gonzalez M.M., Aracil A., Van Schaftingen E., Jaeken J. 3-Phosphoglycerate dehydrogenase deficiency in a patient with West syndrome. Dev. Med. Child Neurol. 2000, 42:629-633.
40. Pinto D., Pagnamenta A.T., Klei L., Anney R., Merico D., Regan R., Conroy J., Magalhaes T.R., Correia C., Abrahams B.S., Almeida J., Bacchelli E., Bader G.D., Bailey A.J., Baird G., Battaglia A., Berney T., Bolshakova N., Bolte S., Bolton P.F., Bourgeron T., Brennan S., Brian J., Bryson S.E., Carson A.R., Casallo G., Casey J., Chung B.H., Cochrane L., Corsello C., Crawford E.L., Crossett A., Cytrynbaum C., Dawson G., de Jonge M., Delorme R., Drmic I., Duketis E., Duque F., Estes A., Farrar P., Fernandez B.A., Folstein S.E., Fombonne E., Freitag C.M., Gilbert J., Gillberg C., Glessner J.T., Goldberg J., Green A., Green J., Guter S.J., Hakonarson H., Heron E.A., Hill M., Holt R., Howe J.L., Hughes G., Hus V., Igliozzi R., Kim C., Klauck S.M., Kolevzon A., Korvatska O., Kustanovich V., Lajonchere C.M., Lamb J.A., Laskawiec M., Leboyer M., Le Couteur A., Leventhal B.L., Lionel A.C., Liu X.Q., Lord C., Lotspeich L., Lund S.C., Maestrini E., Mahoney W., Mantoulan C., Marshall C.R., McConachie H., McDougle C.J., McGrath J., McMahon W.M., Merikangas A., Migita O., Minshew N.J., Mirza G.K., Munson J., Nelson S.F., Noakes C., Noor A., Nygren G., Oliveira G., Papanikolaou K., Parr J.R., Parrini B., Paton T., Pickles A., Pilorge M., Piven J., Ponting C.P., Posey D.J., Poustka A., Poustka F., Prasad A., Ragoussis J., Renshaw K., Rickaby J., Roberts W., Roeder K., Roge B., Rutter M.L., Bierut L.J., Rice J.P., Salt J., Sansom K., Sato D., Segurado R., Sequeira A.F., Senman L., Shah N., Sheffield V.C., Soorya L., Sousa I., Stein O., Sykes N., Stoppioni V., Strawbridge C., Tancredi R., Tansey K., Thiruvahindrapduram B., Thompson A.P., Thomson S., Tryfon A., Tsiantis J., Van Engeland H., Vincent J.B., Volkmar F., Wallace S., Wang K., Wang Z., Wassink T.H., Webber C., Weksberg R., Wing K., Wittemeyer K., Wood S., Wu J., Yaspan B.L., Zurawiecki D., Zwaigenbaum L., Buxbaum J.D., Cantor R.M., Cook E.H., Coon H., Cuccaro M.L., Devlin B., Ennis S., Gallagher L., Geschwind D.H., Gill M., Haines J.L., Hallmayer J., Miller J., Monaco A.P., Nurnberger J.I., Paterson A.D., Pericak-Vance M.A., Schellenberg G.D., Szatmari P., Vicente A.M., Vieland V.J., Wijsman E.M., Scherer S.W., Sutcliffe J.S., Betancur C. Functional impact of global rare copy number variation in autism spectrum disorders. Nature 2010, 466:368-372.
41. Sawa A. Cortical development and glutamatergic dysregulation in schizophrenia. Biol. Psychiatry 2009, 66:530-532.
42. Saxe J.P., Wu H., Kelly T.K., Phelps M.E., Sun Y.E., Kornblum H.I., Huang J. A phenotypic small-molecule screen identifies an orphan ligand-receptor pair that regulates neural stem cell differentiation. Chem. Biol. 2007, 14:1019-1030.
43. Schumacher J., Jamra R.A., Freudenberg J., Becker T., Ohlraun S., Otte A.C., Tullius M., Kovalenko S., Bogaert A.V., Maier W., Rietschel M., Propping P., Nothen M.M., Cichon S. Examination of G72 and d-amino-acid oxidase as genetic risk factors for schizophrenia and bipolar affective disorder. Mol. Psychiatry 2004, 9:203-207.
44. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., Hergueta T., Baker R., Dunbar G.C. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 1998, 59(Suppl. 20):34-57. (22-33, quiz).
45. Tsai G.E., Yang P., Chang Y.C., Chong M.Y. d-alanine added to antipsychotics for the treatment of schizophrenia. Biol. Psychiatry 2006, 59:230-234.
46. Veiga-da-Cunha M., Collet J.F., Prieur B., Jaeken J., Peeraer Y., Rabbijns A., Van Schaftingen E. Mutations responsible for 3-phosphoserine phosphatase deficiency. Eur. J. Hum. Genet. 2004, 12:163-166.
47. Visser R., Gijsbers A., Ruivenkamp C., Karperien M., Reeser H.M., Breuning M.H., Kant S.G., Wit J.M. Genome-wide SNP array analysis in patients with features of sotos syndrome. Horm. Res. Paediatr. 2010, 73:265-274.
48. Walsh T., McClellan J.M., McCarthy S.E., Addington A.M., Pierce S.B., Cooper G.M., Nord A.S., Kusenda M., Malhotra D., Bhandari A., Stray S.M., Rippey C.F., Roccanova P., Makarov V., Lakshmi B., Findling R.L., Sikich L., Stromberg T., Merriman B., Gogtay N., Butler P., Eckstrand K., Noory L., Gochman P., Long R., Chen Z., Davis S., Baker C., Eichler E.E., Meltzer P.S., Nelson S.F., Singleton A.B., Lee M.K., Rapoport J.L., King M.C., Sebat J. Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science 2008, 320:539-543.
49. WTCCC Genome-wide association study of 14,000 cases of seven common diseases and 3000 shared controls. Nature 2007, 447:661-678.
50. Yamada K., Ohnishi T., Hashimoto K., Ohba H., Iwayama-Shigeno Y., Toyoshima M., Okuno A., Takao H., Toyota T., Minabe Y., Nakamura K., Shimizu E., Itokawa M., Mori N., Iyo M., Yoshikawa T. Identification of multiple serine racemase (SRR) mRNA isoforms and genetic analyses of SRR and DAO in schizophrenia and d-serine levels. Biol. Psychiatry 2005, 57:1493-1503.
51. Zhang D., Cheng L., Qian Y., Alliey-Rodriguez N., Kelsoe J.R., Greenwood T., Nievergelt C., Barrett T.B., McKinney R., Schork N., Smith E.N., Bloss C., Nurnberger J., Edenberg H.J., Foroud T., Sheftner W., Lawson W.B., Nwulia E.A., Hipolito M., Coryell W., Rice J., Byerley W., McMahon F., Schulze T.G., Berrettini W., Potash J.B., Belmonte P.L., Zandi P.P., McInnis M.G., Zollner S., Craig D., Szelinger S., Koller D., Christian S.L., Liu C., Gershon E.S. Singleton deletions throughout the genome increase risk of bipolar disorder. Mol. Psychiatry 2009, 14:376-380.